Terms: = Endocrine gland cancer AND CXCR4, D2S201E, 7852, ENSG00000121966, P61073, NPYY3R, NPY3R, HM89, NPYRL, LESTR, HSY3RR, LCR1, fusin, WHIM, NPYR, FB22, CD184 AND Treatment
118 results:
1. The nanobody targeting PD-L1 and cxcr4 counteracts pancreatic stellate cell-mediated tumour progression by disrupting tumour microenvironment.
Li Y; Zheng Y; Xu S; Hu H; Peng L; Zhu J; Wu M
Int Immunopharmacol; 2024 May; 132():111944. PubMed ID: 38581990
[TBL] [Abstract] [Full Text] [Related]
2. Exploring Theranostic Avenues in Adrenocortical Carcinoma Using Chemokine Receptor and Prostate-Specific Membrane Antigen-Directed PET/CT.
Hahner S; Higuchi T; Serfling SE; Samnick S; Fuss CT; Heinze B; Buck AK; Schirbel A; Fassnacht M; Werner RA
Clin Nucl Med; 2024 Apr; 49(4):369-370. PubMed ID: 38350087
[TBL] [Abstract] [Full Text] [Related]
3. Unraveling the impact of cancer-associated fibroblasts on hypovascular pancreatic neuroendocrine tumors.
Lai TY; Chiang TC; Lee CY; Kuo TC; Wu CH; Chen YI; Hu CM; Maskey M; Tang SC; Jeng YM; Tien YW; Lee EYP; Lee WH
Br J Cancer; 2024 Apr; 130(7):1096-1108. PubMed ID: 38341509
[TBL] [Abstract] [Full Text] [Related]
4. Tissue Expression and Prognostic Role of CXCL12 and cxcr4 in High-grade Serous Ovarian Carcinoma.
Lim H; Kim SI; Kim EN; Lee M; Lee C; Kim JW; Chung HH
Anticancer Res; 2023 Jul; 43(7):3331-3340. PubMed ID: 37351997
[TBL] [Abstract] [Full Text] [Related]
5. Effect of tocopherol conjugation on polycation-mediated siRNA delivery to orthotopic pancreatic tumors.
Tang S; Kapoor E; Ding L; Yu A; Tang W; Hang Y; Smith LM; Sil D; Oupický D
Biomater Adv; 2023 Feb; 145():213236. PubMed ID: 36512927
[TBL] [Abstract] [Full Text] [Related]
6. Exosomal miR-655-3p inhibits growth, and invasion and macrophage M2 polarization through targeting cxcr4 in papillary thyroid carcinoma.
Qiao L; Dong C; Jia W; Ma B
Acta Biochim Pol; 2022 Dec; 69(4):773-779. PubMed ID: 36512648
[TBL] [Abstract] [Full Text] [Related]
7. The prognostic significance of cxcr4 and SDF-1 in differentiated thyroid cancer depends on CD8+ density.
Wilhelm A; Lemmenmeier I; Lalos A; Posabella A; Kancherla V; Piscuoglio S; Delko T; von Flüe M; Glatz K; Droeser RA
BMC Endocr Disord; 2022 Nov; 22(1):292. PubMed ID: 36419107
[TBL] [Abstract] [Full Text] [Related]
8. cxcr4-CXCL12-CXCR7 and PD-1/PD-L1 in Pancreatic cancer: CXCL12 Predicts Survival of Radically Resected Patients.
D'Alterio C; Giardino A; Scognamiglio G; Butturini G; Portella L; Guardascione G; Frigerio I; Montella M; Gobbo S; Martignoni G; Napolitano V; De Vita F; Tatangelo F; Franco R; Scala S
Cells; 2022 Oct; 11(21):. PubMed ID: 36359736
[TBL] [Abstract] [Full Text] [Related]
9. Tumour inhibitory activity on pancreatic cancer by bispecific nanobody targeting PD-L1 and cxcr4.
Hao S; Xu S; Li L; Li Y; Zhao M; Chen J; Zhu S; Xie Y; Jiang H; Zhu J; Wu M
BMC Cancer; 2022 Oct; 22(1):1092. PubMed ID: 36284271
[TBL] [Abstract] [Full Text] [Related]
10. The role of selected molecular factors in ovarian cancer metastasis.
Markowska A; Sawicki W; Zurawski J; Fechner J; Markowska J
Ginekol Pol; 2022; 93(8):670-674. PubMed ID: 35894484
[TBL] [Abstract] [Full Text] [Related]
11. Comparative evaluation of somatostatin and cxcr4 receptor expression in different types of thyroid carcinoma using well-characterised monoclonal antibodies.
Czajkowski M; Kaemmerer D; Sänger J; Sauter G; Wirtz RM; Schulz S; Lupp A
BMC Cancer; 2022 Jul; 22(1):740. PubMed ID: 35799158
[TBL] [Abstract] [Full Text] [Related]
12. Dual Stromal Targeting Sensitizes Pancreatic Adenocarcinoma for Anti-Programmed Cell Death Protein 1 Therapy.
Blair AB; Wang J; Davelaar J; Baker A; Li K; Niu N; Wang J; Shao Y; Funes V; Li P; Pachter JA; Maneval DC; Dezem F; Plummer J; Chan KS; Gong J; Hendifar AE; Pandol SJ; Burkhart R; Zhang Y; Zheng L; Osipov A
Gastroenterology; 2022 Nov; 163(5):1267-1280.e7. PubMed ID: 35718227
[TBL] [Abstract] [Full Text] [Related]
13. cxcr4 knockdown enhances sensitivity of paclitaxel via the PI3K/Akt/mTOR pathway in ovarian carcinoma.
Zi D; Li Q; Xu CX; Zhou ZW; Song GB; Hu CB; Wen F; Yang HL; Nie L; Zhao X; Tan J; Zhou SF; He ZX
Aging (Albany NY); 2022 Jun; 14(11):4673-4698. PubMed ID: 35681259
[TBL] [Abstract] [Full Text] [Related]
14. Effect of bevacizumab combined with chemotherapy on SDF-1 and cxcr4 in epithelial ovarian cancer and its prognosis.
Ma C
World J Surg Oncol; 2022 May; 20(1):154. PubMed ID: 35545781
[TBL] [Abstract] [Full Text] [Related]
15. cxcr4 expression in tumor associated cells in blood is prognostic for progression and survival in pancreatic cancer.
Gardner KP; Tsai S; Aldakkak M; Gironda S; Adams DL
PLoS One; 2022; 17(3):e0264763. PubMed ID: 35259193
[TBL] [Abstract] [Full Text] [Related]
16. Nanoemulsion-Assisted siRNA Delivery to Modulate the Nervous Tumor Microenvironment in the treatment of Pancreatic cancer.
Ding L; Tang S; Yu A; Wang A; Tang W; Jia H; Oupický D
ACS Appl Mater Interfaces; 2022 Mar; 14(8):10015-10029. PubMed ID: 35188730
[TBL] [Abstract] [Full Text] [Related]
17. Enhanced CXCL12/cxcr4 signaling increases tumor progression in radiation‑resistant pancreatic cancer.
Kato T; Matsuo Y; Ueda G; Murase H; Aoyama Y; Omi K; Hayashi Y; Imafuji H; Saito K; Morimoto M; Ogawa R; Takahashi H; Takiguchi S
Oncol Rep; 2022 Apr; 47(4):. PubMed ID: 35119076
[TBL] [Abstract] [Full Text] [Related]
18. Optimization strategy of Bacillus subtilis MT453867 levansucrase and evaluation of levan role in pancreatic cancer treatment.
Gamal AA; Abbas HY; Abdelwahed NAM; Kashef MT; Mahmoud K; Esawy MA; Ramadan MA
Int J Biol Macromol; 2021 Jul; 182():1590-1601. PubMed ID: 34015407
[TBL] [Abstract] [Full Text] [Related]
19. Future of immunotherapy in pancreas cancer and the trials, tribulations and successes thus far.
Wong W; Alouani E; Wei A; Ryu YK; Chabot JA; Manji GA
Semin Oncol; 2021 Feb; 48(1):57-68. PubMed ID: 33965249
[TBL] [Abstract] [Full Text] [Related]
20. Different chemokine profile between systemic and testicular diffuse large B-cell lymphoma.
Ollikainen RK; Kotkaranta PH; Kemppainen J; Teppo HR; Kuitunen H; Pirinen R; Turpeenniemi-Hujanen T; Kuittinen O; Kuusisto MEL
Leuk Lymphoma; 2021 Sep; 62(9):2151-2160. PubMed ID: 33856274
[TBL] [Abstract] [Full Text] [Related]
[Next]
